Literature DB >> 11078288

Five or more years of survival in patients with primary systemic amyloidosis and biopsy-proven cardiac involvement.

M Grogan1, M A Gertz, R A Kyle, A J Tajik.   

Abstract

Survival of > or =5 years was seen in 8 of 153 patients (5%) with primary systemic amyloidosis and cardiac involvement. All patients with survival of >5 years received chemotherapy and all but 1 had an objective chemotherapeutic response.

Entities:  

Mesh：

Year:  2000        PMID： 11078288     DOI： 10.1016/s0002-9149(99)00832-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  8 in total

1.  Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience.

Authors:  Martha Grogan; Morie Gertz; Arleigh McCurdy; Lindsey Roeker; Robert Kyle; Sudhir Kushwaha; Richard Daly; Joseph Dearani; Richard Rodeheffer; Robert Frantz; Martha Lacy; Suzanne Hayman; Christopher McGregor; Brooks Edwards; Angela Dispenzieri
Journal:  World J Transplant       Date:  2016-06-24

Review 2.  Treatment of immunoglobulin light chain amyloidosis.

Authors:  Morie A Gertz; Steven R Zeldenrust
Journal:  Curr Hematol Malig Rep       Date:  2009-04       Impact factor: 3.952

3.  Current therapeutic strategies in cardiac amyloidosis.

Authors:  Shailja Parikh; James A de Lemos
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-12

4.  Stiff heart syndrome.

Authors:  Satya S Bhupathi; Sreelatha Chalasani; Roxann Rokey
Journal:  Clin Med Res       Date:  2010-09-17

Review 5.  Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management.

Authors:  Walid Hassan; Hani Al-Sergani; Walid Mourad; Rashed Tabbaa
Journal:  Tex Heart Inst J       Date:  2005

6.  Echocardiographic features of an atypical presentation of rapidly progressive cardiac amyloidosis.

Authors:  Jasper J Brugts; Jaco Houtgraaf; Bouke Pc Hazenberg; Marcel Jm Kofflard
Journal:  World J Cardiol       Date:  2013-05-26

7.  Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis.

Authors:  Kilian Fischer; Nicolas Lellouche; Thibaud Damy; Raphaël Martins; Nicolas Clementy; Arnaud Bisson; François Lesaffre; Madeline Espinosa; Rodrigue Garcia; Bruno Degand; Guillaume Serzian; François Jourda; Olivier Huttin; Jean-Baptiste Guichard; Hervé Devilliers; Jean-Christophe Eicher; Gabriel Laurent; Charles Guenancia
Journal:  ESC Heart Fail       Date:  2021-11-03

8.  Amiloidosis, a mysterious disease, still underestimated.

Authors:  Mircea Penescu
Journal:  J Med Life       Date:  2008 Apr-Jun
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.